Verona Pharma (VRNA) PT Lowered to $50 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mailGet Alerts VRNA Hot Sheet
Price: $106.91 --0%
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 26 | Down: 19 | New: 65
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 26 | Down: 19 | New: 65
Join SI Premium – FREE
Wedbush analyst Liana Moussatos lowered the price target on Verona Pharma (NASDAQ: VRNA) to $50.00 (from $60.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Titan Co Ltd (TTAN:IN) PT Lowered to INR5,540 at JPMorgan
- Live Oak Bancshares (LOB) PT Lowered to $38 at Piper Sandler
- Amazon.com (AMZN) PT Raised to $385 at Tigress Financial Partners
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Liana MoussatosSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
